SLC5A2 and diabetic kidney disease: Interestingly, a recent study showed that SGLT2 inhibitor dapagliflozin promoted angiogenesis by upregulating VEGF expression, resulting in improved pathological findings and kidney function in the early‐stage diabetic nephropathy using a rat model of type 2 diabetes.31